Winton Group
MBX icon

Winton Group’s MBX Biosciences MBX Stock Holding History

Winton Group’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$804K Buy
+13,718
New +$859K 0.03% 540

Other funds holding MBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
NVP Associates
NVP Associates Menlo Park, California $282M AUM 85.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Aaron Wealth Advisors
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return

Winton Group's MBX Position: Q3 2026 in Review

Winton Group opened a new position in MBX Biosciences (MBX) in Q3 2026: 13,718 shares worth $804K. The stake represents 0.03% of the portfolio and ranks #540 among its holdings.

130 funds tracked by Wall St. Rank hold MBX as of Q3 2026.

  • Winton Group held 13,718 shares of MBX Biosciences worth $804K as of Q3 2026.
  • MBX Biosciences was a new Winton Group position in Q3 2026.
  • MBX Biosciences made up 0.03% of Winton Group's portfolio in Q3 2026, its #540 holding.
  • 130 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2026.

Based on Winton Group's 13F filing for Q3 2026, filed 12 Nov 2026.